Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04891757 · ClinicalTrials.gov registry record · Phase 1
FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies
A Phase 1 study of Refractory Acute Myeloid Leukemia and Refractory Chronic Myelomonocytic Leukemia, sponsored by Foghorn Therapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 144
- Enrollment target
- 5
- Study locations
NCT04891757: Active Phase 1 study of Refractory Acute Myeloid Leukemia and Refractory Chronic Myelomonocytic Leukemia, sponsored by Foghorn Therapeutics.
NCT04891757 is a Phase 1 study of Refractory Acute Myeloid Leukemia and Refractory Chronic Myelomonocytic Leukemia that is active but no longer recruiting, run by Foghorn Therapeutics. The registered enrollment target is 144 participants, above the 45-participant average among 63 other Refractory Acute Myeloid Leukemia trials with a reported enrollment target (220% higher). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04891757, a Phase 1 study of Refractory Acute Myeloid Leukemia and Refractory Chronic Myelomonocytic Leukemia, is active but no longer recruiting, sponsored by Foghorn Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 144 participants
- Enrollment target
- 5
- Study locations
Study Summary
This Phase 1, multicenter, open-label, dose escalation study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of FHD-286 administered orally as monotherapy or combination therapy, in subjects with advanced hematologic malignancies.
Conditions Studied
Interventions
- DRUG Decitabine
- DRUG FHD-286
- DRUG Low Dose Cytarabine
Study Locations (5)
California
- City of Hope National Medical Center - Duarte
Massachusetts
- Dana Farber Cancer Institute - Boston
New York
- Memorial Sloan Kettering Cancer Center - New York
Tennessee
- Vanderbilt University Medical Center - Nashville
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 144 participants |
| Start Date | 2021-06-14 |
| Est. Completion | 2027-06 |
| Phase | Phase 1 |
What the registry record for NCT04891757 still lists
NCT04891757 is an interventional study that assigns participants to a tested intervention. The registered 144 participants enrollment target is mid-sized for trials with a published cap, above the 45-participant average among 63 other Refractory Acute Myeloid Leukemia trials with a reported enrollment target (220% higher).
The record links to 7 conditions, with Refractory Acute Myeloid Leukemia appearing as the primary indexed condition, and to 3 interventions - of which Decitabine is the first listed.
NCT04891757 lists 5 locations in 5 states (California, Massachusetts, New York).
Frequently Asked Questions
What is clinical trial NCT04891757 about?
NCT04891757 is a clinical study titled "FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies". This Phase 1, multicenter, open-label, dose escalation study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of FHD-286 administered orally as monotherapy or combination therapy, in subjects with advanced hematologic mal...
What is the current status of trial NCT04891757?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 144 participants. The study started on 2021-06-14. Estimated completion is 2027-06.
What conditions does trial NCT04891757 study?
This clinical trial studies the following conditions: Refractory Acute Myeloid Leukemia, Refractory Chronic Myelomonocytic Leukemia, Relapsed Acute Myeloid Leukemia, Refractory Myelodysplastic Syndromes, Relapsed Myelodysplastic Syndromes.
What interventions are being tested in trial NCT04891757?
The interventions under investigation include: Decitabine (DRUG), FHD-286 (DRUG), Low Dose Cytarabine (DRUG).
Who is sponsoring clinical trial NCT04891757?
This trial is sponsored by Foghorn Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04891757 being conducted?
This trial has 5 study locations across California, Massachusetts, New York, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Refractory Acute Myeloid Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04891757's enrollment target sits among peer trials
144 3rd of 63 higher than 61 of 63 other Refractory Acute Myeloid Leukemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Refractory Acute Myeloid Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia
RECRUITING · Phase 1
-
Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia
RECRUITING · Phase 1
-
Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
RECRUITING · Phase 1
-
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
RECRUITING · Phase 1
-
Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
RECRUITING · Phase 1
-
8-Chloroadenosine in Combination With Venetoclax for the Treatment of Patients With Relapsed/Refractory Acute Myeloid Leukemia
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01861106 · 144 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations
- NCT03482245 · 144 participants · NA
The Role of Circadian Clock Proteins in Innate and Adaptive Immunity
- NCT03504683 · 144 participants · NA
MEAL TIMING Study: Effect of Time-Restricted Feeding on 24-hour Glycemic Control, Blood Pressure, and Cardiovascular Disease Risk Factors in Adults With Prediabetes
- NCT03905603 · 144 participants · Early Phase 1
Relative Contributions of Predictors of Hyperandrogenism in Older vs. Young Women With PCOS
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI